Dapagliflozin Safe, Protective in Advanced Kidney Disease Dapagliflozin Safe, Protective in Advanced Kidney Disease

' For clinicians, this is now the absolute reassurance that we do not have to stop an SGLT2 inhibitor ' in patients with advanced kidney disease, said Dr Chantal Mathieu, about the DAPA-CKD trial.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news